Quick Answer
Vanda Pharmaceuticals Inc. reported Diluted EPS of $3.74 per share (loss) for fiscal year 2025.
Vanda Pharmaceuticals Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.74 | -1033.3% |
| 2024 | -$0.33 | -925.0% |
| 2023 | $0.04 | -63.6% |
| 2022 | $0.11 | -81.0% |
| 2021 | $0.58 | +38.1% |
| 2020 | $0.42 | -80.1% |
| 2019 | $2.11 | +339.6% |
| 2018 | $0.48 | +237.1% |
| 2017 | -$0.35 | +14.6% |
| 2016 | -$0.41 | +56.4% |
| 2015 | -$0.94 | -270.9% |
| 2014 | $0.55 | +179.7% |
| 2013 | -$0.69 | +31.7% |
| 2012 | -$1.01 | -188.6% |
| 2011 | -$0.35 | -240.0% |
| 2010 | $0.25 | +118.8% |
| 2009 | -$1.33 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.38 | -322.2% | +17.4% |
| June 30, 2025 | -$0.46 | -475.0% | +8.0% |
| March 31, 2025 | -$0.50 | -614.3% | -455.6% |
| September 30, 2024 | -$0.09 | — | -12.5% |
| June 30, 2024 | -$0.08 | -366.7% | -14.3% |
| March 31, 2024 | -$0.07 | -216.7% | — |
| September 30, 2023 | $0.00 | -100.0% | -100.0% |
| June 30, 2023 | $0.03 | -40.0% | -50.0% |
- Vanda Pharmaceuticals Inc. showed a decrease of -1033.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2009–2025 period, Vanda Pharmaceuticals Inc.’s diluted eps has declined by 181.2% (from $1.33 per share (loss) to $3.74 per share (loss)).
- The most recent figure is from Vanda Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: